166 related articles for article (PubMed ID: 35493709)
1. In silico prediction and experimental evaluation of potential siRNAs against SARS-CoV-2 inhibition in Vero E6 cells.
Sartaj Sohrab S; Aly El-Kafrawy S; Ibraheem Azhar E
J King Saud Univ Sci; 2022 Jun; 34(4):102049. PubMed ID: 35493709
[TBL] [Abstract][Full Text] [Related]
2. Effect of insilico predicted and designed potential siRNAs on inhibition of SARS-CoV-2 in HEK-293 cells.
Sohrab SS; El-Kafrawy SA; Azhar EI
J King Saud Univ Sci; 2022 Jun; 34(4):101965. PubMed ID: 35313445
[TBL] [Abstract][Full Text] [Related]
3.
Sohrab SS; Aly El-Kafrawy S; Mirza Z; Hassan AM; Alsaqaf F; Azhar EI
Saudi J Biol Sci; 2021 Feb; 28(2):1348-1355. PubMed ID: 33519276
[TBL] [Abstract][Full Text] [Related]
4. Delivery of siRNAs against MERS-CoV in Vero and HEK-293 cells: A comparative evaluation of transfection reagents.
Sartaj Sohrab S; Aly El-Kafrawy S; Mirza Z; Hassan AM; Alsaqaf F; Ibraheem Azhar E
J King Saud Univ Sci; 2023 Apr; 35(3):102540. PubMed ID: 36624781
[TBL] [Abstract][Full Text] [Related]
5. In Vitro Inhibitory Analysis of Rationally Designed siRNAs against MERS-CoV Replication in Huh7 Cells.
El-Kafrawy SA; Sohrab SS; Mirza Z; Hassan AM; Alsaqaf F; Azhar EI
Molecules; 2021 Apr; 26(9):. PubMed ID: 33947034
[TBL] [Abstract][Full Text] [Related]
6. Designing and evaluation of MERS-CoV siRNAs in HEK-293 cell line.
Sohrab SS; El-Kafrawy SA; Mirza Z; Hassan AM; Alsaqaf F; Azhar EI
J Infect Public Health; 2021 Feb; 14(2):238-243. PubMed ID: 33493920
[TBL] [Abstract][Full Text] [Related]
7. Selection and Validation of siRNAs Preventing Uptake and Replication of SARS-CoV-2.
Friedrich M; Pfeifer G; Binder S; Aigner A; Vollmer Barbosa P; Makert GR; Fertey J; Ulbert S; Bodem J; König EM; Geiger N; Schambach A; Schilling E; Buschmann T; Hauschildt S; Koehl U; Sewald K
Front Bioeng Biotechnol; 2022; 10():801870. PubMed ID: 35309990
[TBL] [Abstract][Full Text] [Related]
8. Novel siRNA therapeutics demonstrate multi-variant efficacy against SARS-CoV-2.
Bowden-Reid E; Ledger S; Zhang Y; Di Giallonardo F; Aggarwal A; Stella AO; Akerman A; Milogiannakis V; Walker G; Rawlinson W; Turville S; Kelleher AD; Ahlenstiel C
Antiviral Res; 2023 Sep; 217():105677. PubMed ID: 37478918
[TBL] [Abstract][Full Text] [Related]
9. Computational study and design of effective siRNAs to silence structural proteins associated genes of Indian SARS-CoV-2 strains.
Madanagopal P; Muthukumar H; Thiruvengadam K
Comput Biol Chem; 2022 Jun; 98():107687. PubMed ID: 35537364
[TBL] [Abstract][Full Text] [Related]
10. In Silico Prediction and Designing of Potential siRNAs to be used as Antivirals Against SARS-CoV-2.
Sohrab SS; El-Kafrawy SA; Abbas AT; Bajrai LH; Azhar EI
Curr Pharm Des; 2021; 27(32):3490-3500. PubMed ID: 33430748
[TBL] [Abstract][Full Text] [Related]
11. Computational Design and Experimental Evaluation of MERS-CoV siRNAs in Selected Cell Lines.
Sohrab SS; El-Kafrawy SA; Mirza Z; Hassan AM; Alsaqaf F; Azhar EI
Diagnostics (Basel); 2023 Jan; 13(1):. PubMed ID: 36611443
[TBL] [Abstract][Full Text] [Related]
12. A computational approach to design potential siRNA molecules as a prospective tool for silencing nucleocapsid phosphoprotein and surface glycoprotein gene of SARS-CoV-2.
Chowdhury UF; Sharif Shohan MU; Hoque KI; Beg MA; Sharif Siam MK; Moni MA
Genomics; 2021 Jan; 113(1 Pt 1):331-343. PubMed ID: 33321203
[TBL] [Abstract][Full Text] [Related]
13. Computational prediction of potential siRNA and human miRNA sequences to silence orf1ab associated genes for future therapeutics against SARS-CoV-2.
Hasan M; Ashik AI; Chowdhury MB; Tasnim AT; Nishat ZS; Hossain T; Ahmed S
Inform Med Unlocked; 2021; 24():100569. PubMed ID: 33846694
[TBL] [Abstract][Full Text] [Related]
14. An in silico analysis of effective siRNAs against COVID-19 by targeting the leader sequence of SARS-CoV-2.
Pandey AK; Verma S
Adv Cell Gene Ther; 2021 Apr; 4(2):e107. PubMed ID: 33786418
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of SARS-CoV replication by siRNA.
Wu CJ; Huang HW; Liu CY; Hong CF; Chan YL
Antiviral Res; 2005 Jan; 65(1):45-8. PubMed ID: 15652970
[TBL] [Abstract][Full Text] [Related]
16. Morphology and morphogenesis of SARS-CoV-2 in Vero-E6 cells.
Barreto-Vieira DF; da Silva MAN; Garcia CC; Miranda MD; Matos ADR; Caetano BC; Resende PC; Motta FC; Siqueira MM; Girard-Dias W; Archanjo BS; Barth OM
Mem Inst Oswaldo Cruz; 2021; 116():e200443. PubMed ID: 33566951
[TBL] [Abstract][Full Text] [Related]
17. Silencing SARS-CoV Spike protein expression in cultured cells by RNA interference.
Zhang Y; Li T; Fu L; Yu C; Li Y; Xu X; Wang Y; Ning H; Zhang S; Chen W; Babiuk LA; Chang Z
FEBS Lett; 2004 Feb; 560(1-3):141-6. PubMed ID: 14988013
[TBL] [Abstract][Full Text] [Related]
18.
Pandey AK; Verma S
Drug Dev Ind Pharm; 2022 Oct; 48(10):539-551. PubMed ID: 36250723
[TBL] [Abstract][Full Text] [Related]
19. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
Fantini J; Chahinian H; Yahi N
Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32405156
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of replication and infection of severe acute respiratory syndrome-associated coronavirus with plasmid-mediated interference RNA.
Ni B; Shi X; Li Y; Gao W; Wang X; Wu Y
Antivir Ther; 2005; 10(4):527-33. PubMed ID: 16038478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
